The therapeutic significance of FVIII for hemophilia A patients, along with the technical challenges associated with production have consequently positioned FVIII as an important target in a number of emerging therapeutic protein technologies.28,29 Combinations of emerging technologies are hoped to provide synergistic improvements to recombinant FVIII productivity, stability, and half-life. The gene discussed is F8; the disease is hemophilia A.